Researchers are sufficiently worried by new study results that they are planning clinical trials involving thousands of people to examine the possible link between Parkinson's disease and statins, the world biggest selling drugs, reports Patrick Walter in Chemistry & Industry, the magazine of the SCI.
Suggestions of a statin link are not new, but the results of a recent study linking low LDL cholesterol to Parkinson's provide the strongest evidence to date that it could be real, because statins work by reducing LDL cholesterol. The study by researchers at University of North Carolina showed that patients with low levels of LDL cholesterol are more than three and a half times more likely to develop Parkinson's disease than those with higher LDL levels.
When asked whether she was concerned by the new results, study leader Xuemei Huang said: 'Yes I am very concerned, which is why I am planning a 16000-patient prospective study to examine the possible role of statins.' Huang was quick to point out, however, that a causal link with statins had not yet been proven. And Yoav Ben-Shlomo, a professor of clinical epidemiology at University of Bristol said that it is also a possibility that LDL cholesterol is a consequence rather than a cause of Parkinson's.
But according to Huang, the well-established link between Parkinson's and apoE2, a gene associated with lower LDL cholesterol, supports her theory that low LDL is the culprit in many cases of Parkinson's.
Huang says that if there is a link with statins, we could see big surges in the number of Parkinson's diagnoses in the next five years, because at that stage, statins will have been in common usage for more than a decade.
Huang's new study will examine the statin link. A total of 16000 patients for whom 20 years of baseline fasting cholesterol measurements are available will be involved. Another large-scale trial investigating a cholesterol link with Parkinson's risk is underway at Harvard. This study differs in that there are no baseline data available for the study group.
Pfizer's statin Lipitor is the world's biggest selling drug with $12.2bn in sales in 2005. Parkinson's has previously been linked with pesticides. Pfizer were unavailable for comment.
Source: Society of Chemical Industry
Related stories:
Pieces coming together in Parkinson's, cholesterol puzzle
In 2006, University of North Carolina at Chapel Hill researchers published a study that found people with low levels of LDL cholesterol are more likely to have Parkinson's disease than people with high LDL levels.
New research shows neuroprotective effect of lovastatin
High cholesterol levels are considered to be a risk factor for cardiovascular disease including stroke. Therefore, many cholesterol lowering drugs have been developed by pharmaceutical companies in recent years. One class of these drugs, statins, has been found to reduce the incidence of stroke and progression of Alzheimer’s disease when prophylactically administered.
Buck research focuses on risk factor for Parkinson's disease
A new study demonstrates that high levels of MAO-B, an enzyme that regulates nerve activity in the brain, cause Parkinson’s-like symptoms in mice genetically engineered to overexpress the protein. Furthermore, drugs currently used as an adjunct therapy for Parkinson’s in humans prevented the development of Parkinson’s symptoms in these same animals. The findings, by scientists at the Buck Institute for Age Research, raise the possibility that humans could be tested to see if they have a risk factor for the progressive, incurable neurodegenerative disorder that affects 1.5 million Americans and receive preventive treatment. The study appears in the February 20 issue of the open-access, online journal, PLoS ONE.
Prions link cholesterol to neurodegeneration
Prion infection of neurons increases the free cholesterol content in cell membranes. A new study published in the online open access journal
BMC Biology suggests that disturbances in membrane cholesterol may be the mechanism by which prions cause neurodegeneration and could point to a role for cholesterol in other neurodegenerative diseases.
Reaching 100 Is Easier Than Suspected
A healthy lifestyle during the early elderly years—including weight management, exercising regularly and not smoking—may be associated with a greater probability of living to age 90 in men, as well as good health and physical function, according to a report in the February 11 issue of
Archives of Internal Medicine.
Brain implants relieve Alzheimer's damage
Genetically engineered cells implanted in mice have cleared away toxic plaques associated with Alzheimer’s disease.
Not so contoversial anymore -- panel says moderate coffee drinking reduces many risks
Although the American Society for Nutrition’s popular “controversy session” at Experimental Biology 2007 focuses on the health effects of coffee drinking, panel chair Dr. James Coughlin, a toxicology/safety consultant at Coughlin & Associates, says that recent advances in epidemiologic and experimental knowledge have transformed many of the negative health myths about coffee drinking into validated health benefits.
When a light goes on during thought processes
(PhysOrg.com) -- Thought processes made visible: An international team of scientists headed by Mazahir Hasan of the Max Planck Institute for Medical Research in Heidelberg has succeeded in optically detecting individual action potentials in the brains of living animals. The scientists introduced fluorescent indicator proteins into the brain cells of mice via viral gene vectors: the illumination of the fluorescent proteins indicates both when and which neurons are communicating with each other.